Pedro Bergo

Pedro Bergo

Auto-generated profile, based on publicly available information

Pedro Bergo

Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) Medical School, Porto Alegre, RS, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMThaís C Muradás
Thaís C Muradás
BABruno Abbadi
Bruno Abbadi
AVAnne D Villela
Anne D Villela
FMFernanda S Macchi
Fernanda S Macchi
PBPedro F Bergo
Pedro F Bergo
VRValnês da Silva Rodrigues-Junior
Valnês da Silva Rodrigues-Junior
New effective compounds for tuberculosis treatment are needed. This study evaluated the effects of a series of quinoxaline-derived chalcones against laboratorial strains and clinical isolates of M. tuberculosis. Six molecules, namely N5, N9, N10, N15, N16, and N23 inhibited the growth of the M. tuberculosis H37Rv laboratorial strain. The three compounds (N9, N15 and N23) with the lowest MIC values were further tested against clinical isolates and laboratory strains with mutations in katG or inhA genes. From these data, N9 was selected as the lead compound for further investigation. Importantly, this chalcone displayed a synergistic effect when combined with moxifloxacin. Noteworthy, the anti-tubercular effects of N9 did not rely on inhibition of mycolic acids synthesis, circumventing important mechanisms of resistance. Interactions with cytochrome P450 isoforms and toxic effects were assessed in silico and in vitro. The chalcone N9 was not predicted to elicit any mutagenic, genotoxic, irritant, or reproductive effects, according to in silico analysis. Additionally, N9 did not cause mutagenicity or genotoxicity, as revealed by Salmonella/microsome and alkaline comet assays, respectively. Moreover, N9 did not inhibit the cytochrome P450 isoforms CYP3A4/5, CYP2C9, and CYP2C19. N9 can be considered a potential lead molecule for development of a new anti-tubercular therapeutic agent.

1 March 2018 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
PDF file
EGEduardo C. Gomes
Eduardo C. Gomes
DFDiego Rodrigues Falci
Diego Rodrigues Falci
PBPedro Bergo
Pedro Bergo
AZAlexandre P. Zavascki
Alexandre P. Zavascki
MRMaria Helena Rigatto
Maria Helena Rigatto

1 March 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
ABAndressa Barros
Andressa Barros
HMHilda Monroy
Hilda Monroy
PBPedro Bergo
Pedro Bergo
EBEduarda Beck
Eduarda Beck
LDLeonardo David
Leonardo David
MRMaria Helena Rigatto
Maria Helena Rigatto
This study analysed the impact of antimicrobial stewardship team (AST) evaluation on time to susceptible in vitro therapy and mortality of patients with carbapenem-resistant Enterobacterales (CRE) bacteraemia. We performed a retrospective cohort study (February 2018 to July 2020) to evaluate the impact of AST evaluation, along with other clinical and microbiological variables, on time to appropriate antibiotics, 14-day mortality and in-hospital mortality in patients aged >18 years with CRE bacteraemia. A Cox regression model was used for multivariate analysis. A total of 142 patients were included. The proportion of patients who received appropriate antibiotics in the first 5 days after bacteraemia was 82/92 (89.1%) versus 29/50 (58.0%) evaluated and not evaluated by the AST, respectively (P < 0.01). AST evaluation reduced the median time to appropriate therapy (49.8 h vs. 71.1 h; P = 0.01). AST intervention was independently associated with earlier prescription of appropriate therapy (P = 0.02) when controlled for septic shock (P < 0.01) and CRE isolation in the previous 90 days (P = 0.04). Regarding mortality, 51 patients (35.9%) died within 14 days (25.8% vs. 44.7% with and without AST intervention, respectively; P = 0.02) and 82 patients (57.7%) in hospital (52.2% vs. 68.0% evaluated and not evaluated by the AST, respectively; P = 0.08). AST intervention was independently protective for 14-day mortality (P = 0.03) when controlled for septic shock status (P < 0.01). AST guidance improves the quality of antibiotic prescriptions and clinical outcomes in patients with CRE bacteraemia.